Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders

Engin Emrem Bestepe, Nazlı Tunali, Gökçe Elif Sarıdoğan Department of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Istanbul, TurkeyCorrespondence: Gökçe Elif SarıdoğanDepartment of P...

Full description

Bibliographic Details
Main Authors: Bestepe EE, Tunali N, Sarıdoğan GE
Format: Article
Language:English
Published: Dove Medical Press 2020-11-01
Series:Neuropsychiatric Disease and Treatment
Subjects:
Online Access:https://www.dovepress.com/sexual-adverse-effects-and-erectile-dysfunction-during-buprenorphinena-peer-reviewed-article-NDT
_version_ 1818684292290576384
author Bestepe EE
Tunali N
Sarıdoğan GE
author_facet Bestepe EE
Tunali N
Sarıdoğan GE
author_sort Bestepe EE
collection DOAJ
description Engin Emrem Bestepe, Nazlı Tunali, Gökçe Elif Sarıdoğan Department of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Istanbul, TurkeyCorrespondence: Gökçe Elif SarıdoğanDepartment of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Sinan Ercan Cad. No: 23 Kazasker, Istanbul 34736, TurkeyTel +90 532 503 27 97Email drgokcesaridogan@gmail.comBackground and Objectives: Compliance and maintenance of abstinence is a major issue in substance use disorders. Adverse effects of opioid maintenance treatments (OMT) include sexual dysfunctions. There is a vast amount of studies regarding sexual adverse effects of conventional OMTs; however, information regarding buprenorphine/naloxone (Bup/Nal) combination is limited, mostly evaluated in western populations and controversial. In this study, we aimed to assess the sexual adversities of Bup/Nal treatment in a Turkish alcohol and substance use disorder treatment center sample.Materials and Methods: We recruited 100 subjects continuing sublingual Bup/Nal combination and 35 control subjects. Subjects were evaluated via the the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) for sexual dysfunction and for erectile dysfunction (ED) with the International Index of Erectile Function-5 (IIEF-5) as a comparison.Results: The mean dose of our treatment was 9.05. Overall sexual dysfunction scores were not significantly different in between groups with GRISS. ED and noncommunication scores were significantly higher in the Bup/Nal treatment group than the control group (p = 0.002, p = 0.02, respectively). Along with the increased ED scores in GRISS, IIEF-5 total scores also revealed more significant severity of the ED in the Bup/Nal group (p = 0.001).Conclusion: Buprenorphine/naloxone combination lead to a higher degree of ED severity than the non-treatment controls. Noncommunication seems to play a role as a risk factor for ED in patients with opioid use disorder. Thus, effective communication can be a key factor for sexual assertivity and disclosing the sexual adverse effects to the clinicians as well as staying in the treatment.Keywords: buprenorphine maintenance, Turkey, substance-related disorders, men, methadone
first_indexed 2024-12-17T10:48:19Z
format Article
id doaj.art-76791385ec7041bc8f35907c58c1a57f
institution Directory Open Access Journal
issn 1178-2021
language English
last_indexed 2024-12-17T10:48:19Z
publishDate 2020-11-01
publisher Dove Medical Press
record_format Article
series Neuropsychiatric Disease and Treatment
spelling doaj.art-76791385ec7041bc8f35907c58c1a57f2022-12-21T21:52:04ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212020-11-01Volume 162695270559254Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use DisordersBestepe EETunali NSarıdoğan GEEngin Emrem Bestepe, Nazlı Tunali, Gökçe Elif Sarıdoğan Department of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Istanbul, TurkeyCorrespondence: Gökçe Elif SarıdoğanDepartment of Psychiatry, Erenkoy Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences, Sinan Ercan Cad. No: 23 Kazasker, Istanbul 34736, TurkeyTel +90 532 503 27 97Email drgokcesaridogan@gmail.comBackground and Objectives: Compliance and maintenance of abstinence is a major issue in substance use disorders. Adverse effects of opioid maintenance treatments (OMT) include sexual dysfunctions. There is a vast amount of studies regarding sexual adverse effects of conventional OMTs; however, information regarding buprenorphine/naloxone (Bup/Nal) combination is limited, mostly evaluated in western populations and controversial. In this study, we aimed to assess the sexual adversities of Bup/Nal treatment in a Turkish alcohol and substance use disorder treatment center sample.Materials and Methods: We recruited 100 subjects continuing sublingual Bup/Nal combination and 35 control subjects. Subjects were evaluated via the the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) for sexual dysfunction and for erectile dysfunction (ED) with the International Index of Erectile Function-5 (IIEF-5) as a comparison.Results: The mean dose of our treatment was 9.05. Overall sexual dysfunction scores were not significantly different in between groups with GRISS. ED and noncommunication scores were significantly higher in the Bup/Nal treatment group than the control group (p = 0.002, p = 0.02, respectively). Along with the increased ED scores in GRISS, IIEF-5 total scores also revealed more significant severity of the ED in the Bup/Nal group (p = 0.001).Conclusion: Buprenorphine/naloxone combination lead to a higher degree of ED severity than the non-treatment controls. Noncommunication seems to play a role as a risk factor for ED in patients with opioid use disorder. Thus, effective communication can be a key factor for sexual assertivity and disclosing the sexual adverse effects to the clinicians as well as staying in the treatment.Keywords: buprenorphine maintenance, Turkey, substance-related disorders, men, methadonehttps://www.dovepress.com/sexual-adverse-effects-and-erectile-dysfunction-during-buprenorphinena-peer-reviewed-article-NDTbuprenorphine maintenanceturkeysubstance-related disordersmenmethadone
spellingShingle Bestepe EE
Tunali N
Sarıdoğan GE
Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
Neuropsychiatric Disease and Treatment
buprenorphine maintenance
turkey
substance-related disorders
men
methadone
title Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
title_full Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
title_fullStr Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
title_full_unstemmed Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
title_short Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
title_sort sexual adverse effects and erectile dysfunction during buprenorphine naloxone combination treatment for opioid use disorders
topic buprenorphine maintenance
turkey
substance-related disorders
men
methadone
url https://www.dovepress.com/sexual-adverse-effects-and-erectile-dysfunction-during-buprenorphinena-peer-reviewed-article-NDT
work_keys_str_mv AT bestepeee sexualadverseeffectsanderectiledysfunctionduringbuprenorphinenaloxonecombinationtreatmentforopioidusedisorders
AT tunalin sexualadverseeffectsanderectiledysfunctionduringbuprenorphinenaloxonecombinationtreatmentforopioidusedisorders
AT sarıdogange sexualadverseeffectsanderectiledysfunctionduringbuprenorphinenaloxonecombinationtreatmentforopioidusedisorders